According to the Tianyancha App, on September 18th, Johnson&Johnson (China) Investment Co., Ltd. underwent a business change, with Song Weiqun stepping down as the legal representative and chairman, and being succeeded by ZHOU MINTAO.
Johnson&Johnson (China) Investment Co., Ltd. was established in May 1998 with a registered capital of approximately 169 million US dollars. Its business scope includes wholesale and retail of drugs, as well as import and export of drugs. It is jointly owned by Johnson&Johnson of the United States and Janssen Pharmaceuticals of Belgium. In April of this year, Johnson&Johnson announced that Will Song, Chairman of the China region and President of Johnson&Johnson Medical Technology China, had submitted his resignation to Johnson&Johnson.